

CardioMetabolic Diseases

Our innovation in CardioMetabolic diseases is evidenced through our long history of excellence in research and landmark clinical trials, culminating in our most recent breakthrough treatments in type 2 diabetes and anticoagulation care. We are also committed to discovering and developing the innovations of the future and are searching for differentiated novel products and new therapeutic concepts (compound-related research targets or new pathways/ideas), with a preference for discovery up to IND-ready programs.

Our specific partnering interests offer various opportunities for collaboration with a focus on therapies that address microvascular and macrovascular complications of diabetes and the metabolic syndrome.

Liver diseases

- Non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis

Diabetic retinopathy (DME, PDR, nPDR)

Chronic kidney diseases

- Chronic kidney disease, and approaches targeting pathophysiologies in the cardio-renal axis, including heart failure, acute kidney injury, renal inflammation and fibrosis

Novel obesity treatments achieving weight loss > 10%

Breakthrough treatments for type 2 diabetes, Pancreas recovery options

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

**Working together
for better health**

For more information please contact our BD&L team:

Dr. Johannes Zanzinger

johannes.zanzinger@boehringer-ingelheim.com

Dr. Monica Cheng

monica.cheng@boehringer-ingelheim.com

Dr. Manuel Baader

manuel.baader@boehringer-ingelheim.com

